SG10201908587PA - Treatment regimens - Google Patents

Treatment regimens

Info

Publication number
SG10201908587PA
SG10201908587PA SG10201908587PA SG10201908587PA SG 10201908587P A SG10201908587P A SG 10201908587PA SG 10201908587P A SG10201908587P A SG 10201908587PA SG 10201908587P A SG10201908587P A SG 10201908587PA
Authority
SG
Singapore
Prior art keywords
treatment regimens
treatmentregimens
npositions
hsdd
disorders
Prior art date
Application number
Inventor
Nicolas Sitchon
Robert Pyke
John Kaufmann
Original Assignee
S1 Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S1 Pharmaceuticals Inc filed Critical S1 Pharmaceuticals Inc
Publication of SG10201908587PA publication Critical patent/SG10201908587PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TREATMENTREGIMENS The invention further relates to compounds, pharmaceutical co~npositions and methods for treating all disorders of human sexual function including hypoactive sexual desire disorder (HSDD) in a subject.
SG10201908587P 2012-08-06 2013-08-06 Treatment regimens SG10201908587PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261679999P 2012-08-06 2012-08-06

Publications (1)

Publication Number Publication Date
SG10201908587PA true SG10201908587PA (en) 2019-10-30

Family

ID=50068530

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201500919PA SG11201500919PA (en) 2012-08-06 2013-08-06 Treatment regimens
SG10201908587P SG10201908587PA (en) 2012-08-06 2013-08-06 Treatment regimens
SG10201709967YA SG10201709967YA (en) 2012-08-06 2013-08-06 Treatment regimens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201500919PA SG11201500919PA (en) 2012-08-06 2013-08-06 Treatment regimens

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201709967YA SG10201709967YA (en) 2012-08-06 2013-08-06 Treatment regimens

Country Status (15)

Country Link
US (1) US9517254B2 (en)
EP (1) EP2879680A4 (en)
JP (2) JP2015524474A (en)
KR (3) KR20200128437A (en)
CN (2) CN106924259A (en)
AU (2) AU2013299725A1 (en)
BR (1) BR112015002687A2 (en)
CA (1) CA2881388A1 (en)
EA (1) EA201590349A1 (en)
HK (2) HK1211239A1 (en)
IL (1) IL237150B (en)
MX (1) MX2015001695A (en)
SG (3) SG11201500919PA (en)
WO (1) WO2014025814A1 (en)
ZA (1) ZA201501562B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2016001597A1 (en) * 2016-06-17 2017-10-06 S1 Biopharma Inc Methods of treatment of women with hypoactive sexual desire disorders with combination treatment of bupropion and trazodone
US12060328B2 (en) 2022-03-04 2024-08-13 Reset Pharmaceuticals, Inc. Co-crystals or salts of psilocybin and methods of treatment therewith
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687771A (en) * 1985-11-01 1987-08-18 Bristol-Myers Company Method for treatment of male impotence
DE4321965A1 (en) * 1993-07-01 1995-01-12 Cytech Biomedical Inc Oxytocin-containing composition and the use thereof as remedy, in particular nasal spray for the treatment of sexual dysfunctions
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
JP2002322085A (en) * 2001-04-26 2002-11-08 Kazuhito Tomizawa Intelligent dysfunction therapeutic agent
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
WO2004030524A2 (en) * 2002-10-03 2004-04-15 Pr Pharmaceuticals Treatment of autism and similar disorders
JP2007525442A (en) * 2003-03-05 2007-09-06 ピーアール ファーマシューティカルズ，インコーポレイテッド Oxytocin controlled release formulation and method of using oxytocin controlled release formulation
CN1946404A (en) * 2004-04-22 2007-04-11 贝林格尔·英格海姆国际有限公司 Pharmaceutical compositions for the treatment of sexual disorders II
KR20070014184A (en) 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 New pharmaceutical compositions for the treatment of sexual disorders ii
US20060004076A1 (en) 2004-06-30 2006-01-05 Inflabloc Pharmaceuticals, Inc. Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
US9023793B2 (en) 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
JP2010508354A (en) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Treatment of pervasive developmental disorders
WO2008075162A2 (en) 2006-12-15 2008-06-26 Pfizer Limited Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
WO2009016488A2 (en) * 2007-08-02 2009-02-05 Compugen, Ltd. Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
CA2734859A1 (en) * 2008-08-21 2010-02-25 Richter Gedeon Nyrt. Methods for treating cns disorders
DK2389187T3 (en) * 2009-01-20 2017-02-20 Los Angeles Biomedical Res Inst At Harbor-Ucla Medical Center Sorbic and benzoic acid and derivatives thereof to enhance the activity of a neuropharmaceutical
WO2011140608A1 (en) * 2010-05-14 2011-11-17 Keating Charlotte L Neuropsychopharmacological treatment regimes for treating psychological disorders
US20130085106A1 (en) * 2010-05-19 2013-04-04 The University Of North Carolina At Chapel Hill Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders
WO2012016229A2 (en) * 2010-07-30 2012-02-02 The Regents Of The University Of California Oxytocin treatment to improve memory and modify blood glucose
HUE036977T2 (en) * 2011-04-04 2018-08-28 S1 Biopharma Inc Composition for treating hypoactive sexual desire disorder

Also Published As

Publication number Publication date
EP2879680A1 (en) 2015-06-10
KR20230136142A (en) 2023-09-26
JP2018150357A (en) 2018-09-27
KR20150063039A (en) 2015-06-08
US20150150946A1 (en) 2015-06-04
SG10201709967YA (en) 2018-01-30
EA201590349A1 (en) 2015-07-30
HK1211239A1 (en) 2016-05-20
IL237150B (en) 2018-07-31
SG11201500919PA (en) 2015-04-29
MX2015001695A (en) 2015-09-28
HK1214505A1 (en) 2016-07-29
JP2015524474A (en) 2015-08-24
AU2018205121A1 (en) 2018-07-26
AU2013299725A1 (en) 2015-03-26
WO2014025814A1 (en) 2014-02-13
BR112015002687A2 (en) 2019-12-17
EP2879680A4 (en) 2016-06-01
IL237150A0 (en) 2015-04-30
ZA201501562B (en) 2017-11-29
CN104884060A (en) 2015-09-02
KR20200128437A (en) 2020-11-12
US9517254B2 (en) 2016-12-13
CA2881388A1 (en) 2014-02-13
CN106924259A (en) 2017-07-07

Similar Documents

Publication Publication Date Title
MX2019009437A (en) Treatment of myelosuppression.
PH12014501702A1 (en) Imidazopyrrolidinone compounds
PH12015500525A1 (en) Formulations of enzalutamide
MX2015002292A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.
MX2018010548A (en) Dll3 modulators and methods of use.
SG11201504895TA (en) Apparatus with elliptical movement for skin cleansing, stimulation and delivery of treatments
MX2015006234A (en) Use of akkermansia for treating metabolic disorders.
MX2015014438A (en) Methods of using interleukin-10 for treating diseases and disorders.
MY168032A (en) Warm-Cool Beauty Treatment Device
NZ723884A (en) Methods of treating alzheimer’s disease
HK1215173A1 (en) Methods of treating s. aureus-associated diseases
MX2019004364A (en) Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder.
MX2020009966A (en) Dosage forms and therapeutic uses l-4-chlorokynurenine.
SG10201908587PA (en) Treatment regimens
GB2501670B (en) Improvements in or relating to beauty, health, or therapeutic treatments
MX2013011623A (en) Treatment regimens.
MX2016002307A (en) Cancer treatment.
WO2014083432A3 (en) Female intranasal testosterone gel for treating anorgasmia
MX2015008454A (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders.
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
PL2644202T3 (en) Ointment for skin treatment, and method of its manufacture
MX2019009243A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.